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Abstract
Our aim was to evaluate the prevalence of fosfomycin-resistant strains among ESBL-producing Escherichia coli isolates recov-
ered from community patients in Switzerland. A total of 1225 ESBL-producing E. coli isolates were collected between 2012 and
2013 from a private and community laboratory. Fosfomycin resistance was assessed by using the novel rapid fosfomycin/E. coli
NP test and agar dilution method. Resistant isolates were further investigated for acquired resistance genes fosA1–7 by PCR and
sequencing. Pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST) were performed to evaluate the
clonal relationship among fosA3-carrying isolates. Out of the 1225 ESBL-producing E. coli isolates analyzed in this study, 1208
were fosfomycin susceptible while 17 were fosfomycin resistant. No discrepancy was observed between the rapid fosfomycin/
E. coli NP test and the agar dilution method taken as the gold standard. Five out of the 17 resistant isolates carried a fosA-like
gene. No clonal relationship was observed among those isolates. Here, the prevalence of fosfomycin resistance among ESBL-
producing E. coli isolates in the community is reported for the first time in Switzerland, being ca. 1.4%. Among the five isolates
carrying a fosA gene, four encoded the FosA3 enzyme, being the most prevalent fosfomycin-resistant determinant. An excellent
correlation was observed between minimum inhibitory concentration–based susceptibility categorization and results of the rapid
fosfomycin/E. coli NP test, further indicating the excellent sensitivity and specificity of this recently developed rapid test whose
results are obtained in less than 2 h.
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Introduction
On a global scale, it is estimated that urinary tract infections
(UTIs) affect 150 million people per year. Escherichia coli is
the most frequent bacterial species responsible for UTIs. It is
estimated that E. coli causes 75% of uncomplicated and 65%
of complicated UTIs [1]. Due to an increased prevalence rate
of extended-spectrum β-lactamases (ESBLs) conferring resis-
tance to broad-spectrum cephalosporins, and due to the occur-
rence of associated multiple resistance traits in those ESBL-
producing isolates, multidrug-resistant isolates are often iden-
tified nowadays in those urinary pathogens [2–4].
Fosfomycin is a phosphonic acid-derived antibiotic owning
unique structure and mechanism of action, granting for a
broad-spectrum activity and without cross-resistance with oth-
er antibiotics. For these reasons, fosfomycin is a first-line
treatment as oral therapy for uncomplicated UTIs.
Fosfomycin shows good activity against E. coli isolates,
exhibiting a resistance rate estimated to be < 10% [5, 6].
Chromosomally encoded fosfomycin resistance mecha-
nisms in E. coli include reduced drug uptake, due to mutations
in the genes encoding GlpT and UhpT transporters, and mu-
tations in the fosfomycin target which is the enzyme catalyz-
ing the first step in peptidoglycan biosynthesis, namelyMurA.
Reduced drug uptake remains the most frequently
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encountered fosfomycin resistance mechanism not only
among clinical isolates but also among in vitro obtained mu-
tants [7, 8].
Transferable resistance mechanisms in E. coli entail the
FosA metallo-enzymes, responsible for fosfomycin inactiva-
tion by catalyzing the conjugation of glutathione to this anti-
biotic molecule [8]. Among the seven FosA variants reported
so far, four (FosA3, FosA4, FosA5, and FosA6) have been
identified as acquired resistance determinants among E. coli
isolates [9–11]. The FosA3 variant is the most relevant since it
has been extensively reported in humans and animals, mainly
in Asia but also in Europe and the USA [12–14]. The FosA3
encoding gene is located onto conjugative plasmids co-
encoding ESBLs of the CTX-M-type [15]. Hence, selective
pressure with fosfomycin and/or broad-spectrum cephalospo-
rins may lead to acquisition of those plasmid and consequent-
ly to co-resistance to those drugs.
Fosfomycin resistance rates in ESBL-producing E. coli in
Europe, Asia, and the USA is estimated to be low, the average
being ca. 3.2% [5]. However, a Spanish study showed an
increase in fosfomycin resistance rates among ESBL-
producing E. coli from 2.2% in 2004 to 21.7% in 2008, in
parallel to a concomitant 50% increase in fosfomycin con-
sumption [16]. An even higher rate of fosfomycin resistance
of 31.1% in ESBL producers from UTI is now reported from
Israel [17]. To estimate the prevalence of fosfomycin resis-
tance in community-acquired ESBL-producing E. coli isolates
in Switzerland, we have screened a collection of 1225 isolates
recovered in a Swiss laboratory during 2 years. This study was
performed in community settings since this is the most impor-
tant location of E. coli spread. The genetic bases of acquired
fosfomycin resistance have been deciphered, and the clonal
relationship among FosA producers has been evaluated.
Materials and methods
Isolate collection
A total of 1225 ESBL-producing E. coli isolates were collect-
ed from a Swiss private laboratory between 2012 and 2013.
Samples were of different nature, including urine (~ 89%),
genital and anal swabs (~ 4%), stool (~ 3%), and blood cul-
tures (~ 2%). The remaining 2% of the samples were classified
as Bother^ and were of various nature such as expectoration
and abscesses. Samples were recovered from women, men,
and newborns. Ages ranged from 0 to 103 years.
Fosfomycin resistance determination
Two techniques were used to assess fosfomycin susceptibility.
First, the agar dilution method using cation-adjusted Mueller-
Hinton agar (MHA-CA, reference 64884; Bio-Rad, Marnes-
la-Coquette, France), supplemented with 25μg/ml of glucose-
6-phosphate, was used to determine fosfomycin minimum
inhibitory concentration (MIC) over a range of dilutions (1–
512 μg/ml) as recommended by Clinical Laboratory Standard
Institute (CLSI) guidelines [18]. The breakpoints of the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) were used as reference [19]. E. coli iso-
lates withMICs of fosfomycin ≤ 32μg/ml were categorized as
susceptible while those with MICs > 32 μg/ml were catego-
rized as resistant. Uncertain MICs as well as MICs close to the
breakpoint were repeated three times. Second, the rapid
fosfomycin/E. coli NP test was performed as described in
Nordmann et al. [20]. Results were read after 1 h and
30 min of incubation at 35 ± 2 °C. Agar dilution method and
rapid fosfomycin/E. coli NP results were further compared.
FosA role in fosfomycin resistance
The contribution of FosA resistance proteins in fosfomycin
resistance was assessed by using the disk diffusion method
as described in Nakamura et al. [9]. Briefly, ~ 0.5 McFarland
standard of fosfomycin-resistant E. coli isolates were inocu-
lated onto Mueller-Hinter agar plates supplemented with
25 μg/ml of glucose-6-phosphate. Two Kirby-Bauer disks
containing 200 μg of fosfomycin, with and without 0.5 mg
of the FosA-inhibitor sodium phosphonoformate (PPF)
(Sigma-Aldrich), were added on the plates, which were incu-
bated at 35 ± 2 °C O/N. Actually, PPF inhibits selectively the
FosA proteins that allows differentiation between plasmid-
mediated FosA and chromosome-encoded resistance mecha-
nisms to fosfomycin. An increase in the diameter of the
growth inhibition zone by ≥ 5 mm in the presence of PPF is
interpreted as a FosA-related resistance.
PCR amplification and sequencing
Isolates of DNAwere extracted with the QIAamp DNA Mini
Kit and the QIAcube workstation (Qiagen, Courtaboeuf,
France), according to the manufacturer’s instructions. PCR
amplification followed by sequencing (Microsynth, Balgach,
Switzerland) was performed to detect the plasmid-mediated
fosA genes (fosA1 to fosA6) as previously described [20].
The presence of fosA7 gene was investigated with the follow-
ing primers: fosA-7_Fw (5 ′-TGTGGCGACCTTTG
GGTCTG-3′), fosA-7_Rv (5′-AGTTCCAGCTTGTG
GCCATC-3′). PCR conditions were the same as those used
for fosA1–6 gene amplification and described previously.
FosA3-carrying isolates were further screened for CTX-M-
type ESBL presence. Primers CTX-M-A1 (5′-SCS ATG TGC
AGYACCAGTAA-3′) and CTX-M-A2 (5′-GCCGCCGAC
GCTAATACATC-3′) were used to amplify blaCTX-M-1-like
genes (including blaCTX-M-3 and blaCTX-M-15), and primers
CTX-M-9-F (5′-GGT GAC AAA GAG AGT GCA AC-3′)
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and CTX-M-9-R (5′-GCTGGGTAAAATAGGTCACC-3′)
were used to amplify the blaCTX-M-9-like genes. To detect the
blaCTX-M-8 and blaCTX-M-2 genes, primers CTX-M-8-F (5′-
ATG AGA CAT CGC GTT AAG CG-3′) and CTX-M-8-R
(5′-CGT CGT ACC ATA ATC ACC GC-3′), or primers
CTX-M-2-F (5′-TGA TGA CTC AGA GCA TTC GC-3′)
and CTX-M-2-R (5′-AAG TAG GTC ACC AGA ACC AG-
3′), were used, respectively. PCR conditions were 95 °C for 5
min, followed by 30 cycles of 95 °C for 30 s, 52 °C for 30 s,
and 72 °C for 30 s, with a final extension of 72 °C for 5 min.
Sequences were analyzed with CloneManager Professional
(Sci-Ed Software, Denver, CO, USA).
Clonal relationship
Clonal relationship of the bacterial isolates was evaluated by
pulsed-field gel electrophoresis (PFGE). Total DNAs from
five E. coli isolates carrying a plasmid-encoded fosA3 gene
were digested using XbaI enzyme (New England BioLabs,
Ipswich, MA, USA). PFGE was then assessed using the
CHEF-DR III System (Bio-Rad) to separate the digestion-
generated fragments. Finally, multilocus sequence typing
(MLST) was assessed on all E. coli isolates carrying a
FosA-like encoding gene and sequence types (STs) assigned
according to the EnteroBase database (http://mlst.warwick.ac.
uk/mlst/dbs/Ecoli/).
Results
A total of 1225 ESBL-producing E. coli isolates were inves-
tigated for fosfomycin resistance. Seventeen isolates turned to
be positive according to the results of the rapid fosfomycin/
E. coli NP test. Precise determination of their MIC values
showed that, for those strains, fosfomycin MICs ranged from
64 to > 512 μg/ml, further confirming the categorization of
those isolates as being truly fosfomycin resistant (Table 1).
Among them, four isolates possessed the fosA3 gene and a
single isolate possessed the fosA4. Two out of four isolates
carrying a fosA3 gene co-harbored a blaCTX-M-3 gene, one
isolate possessed a blaCTX-M-15 gene, and another single iso-
late possessed the blaCTX-M-9 gene (Table 1). Twelve isolates
remained negative for all the fosA1–7 genes by PCR. Four out
of the five isolates possessing a fosA gene showed accordingly
an increased diameter of the growth inhibition in the presence
of the FosA-inhibitor PPF. Noticeably, two isolates showing
increased diameters around the fosfomycin disk with PPF
remained negative for the fosA1–7 genes (Table 1). Other
mechanisms of resistance to fosfomycin were not further
investigated.
The 1208 fosfomycin-susceptible isolates exhibited MICs
ranging between 1 and 32 μg/ml and accordingly remained
negative for the rapid fosfomycin/E. coliNP test. Overall, it is
interesting to highlight that results of susceptibility testing and
of the rapid fosfomycin/E. coli NP test showed 100% corre-
lation, for both susceptible and resistant isolates. Among
them, 15 isolates exhibited MIC values close to the breakpoint
value (n = 3, MICs of fosfomycin at 64 μg/ml; n = 4, MICs at
128 μg/ml; n = 8, MICs at 32 μg/ml), but nevertheless gave
concordant results with the rapid test.
PFGE and MLST analyses showed no clonal relationship
among the fosfomycin-resistant isolates producing a FosA
enzyme. More precisely, the four isolates carrying the fosA3
gene were of sequence types ST117, ST359 (ST101 com-
plex), ST69, and ST10, while that carrying the fosA4 gene
was of ST12 (Table 1).
Discussion
This is the first study evaluating the prevalence of fosfomycin
resistance among ESBL-producing E. coli in Switzerland. Our
results showed a low prevalence in the community, being ca.
1.4%. This prevalence rate is lower than that reported previ-
ously (a total of 11 distinct studies from 2004 to 2009) from
the USA, Asia, and Europe where the fosfomycin resistance
rate had been estimated to be 3.2% [5]. Even though studies
published after 2010 reported a slight increase in fosfomycin
resistance, the estimated rate is still considered to be below
10% [6]. This lower fosfomycin resistance rate observed
among community-acquired pathogens in Switzerland may
mirror the overall low resistance levels observed for many
pathogens in Switzerland (www.anresis.ch). Additionally,
differences in fosfomycin use might also reflect differences
in fosfomycin resistance. A former Swiss study evaluating
antimicrobial resistance among E. coli isolates recovered
from E. coli in a tertiary care hospital between 2012 and
2015 reports a fosfomycin resistance rate of 0.9% [21].
However, the prevalence fosfomycin rate among ESBL vs
non-ESBL E. coli producers had not been evaluated.
Considering the general low prevalence of fosfomycin re-
sistance observed in this study and in other studies performed
from 2004 to 2015 [5, 6], we may speculate that there is an
overall low risk of rapid expansion of fosfomycin resistance
among ESBL-producing E. coli. Nevertheless, the analysis
reported in the current study was performed on samples col-
lected between 2012 and 2013, and might not reflect the con-
temporary fosfomycin resistance rate. Further studies are
therefore needed to confirm a low fosfomycin resistance
among ESBL-producing E. coli in Switzerland in 2019.
Our data highlights that 29% of the fosfomycin-resistant
ESBL-producing E. coli isolates possess a fosA gene. These
isolates were clonally unrelated, exhibiting different clonal
profiles and sequence types, suggesting that acquired
plasmid-encoded FosA-related resistance occurred through
independent genetic events.
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The FosA3 enzyme was first identified in Japan, from an
E. coli isolate collected between 2002 and 2007 [12]. In 2010,
this enzyme was observed in an E. coli isolate in the USA
[13], then in France [15] and in Switzerland (this study) in
2012, highlighting its worldwide dissemination. Intriguingly,
similar to one isolate from 2013 carrying the fosA3 gene de-
tected in our study, another FosA3-producing ST69 E. coli
had been recovered in France in 2014, suggesting a clonal
relationship [15].
As expected, the majority (80%) of FosA-producing E. coli
analyzed in our study carried a fosA3 gene, confirming that
this is the most prevalent plasmid-mediated fosfomycin resis-
tance gene variant among E. coli, including among ESBL
producers. Isolates carrying a FosA3-encoding gene also car-
ried produced CTX-M-type ESBLs, being of either CTX-M-
3-, CTX-M-15-, or CTX-M-9-types, further highlighting that
associations between fosA3 and blaCTX-M genes are frequent,
as widely reported [12, 14, 22].
Noteworthily, two E. coli ESBL-producing isolates exhib-
ited an increased inhibition zone diameter on the agar plate in
the presence of PPF (positive result), but remained negative
for fosA1–7 amplification, suggesting the possible production
of still unknown FosA-related or FosA-unrelated resistance
mechanism(s).
Surprisingly, for a single E. coli isolate carrying a fosA3
gene, the PPF test remained negative, suggesting that the phe-
notypic resistance observed might be resulting from both a
plasmid-encoded and a chromosomally encoded resistance
mechanism(s). The other possibility is that this PPF-
mediated inhibition might lack the sensitivity for detecting
FosA-related resistance to fosfomycin.
It has been suggested that mutations in several chromosom-
al genes involved in fosfomycin resistance in E. coli clinical
isolates might have an elevated biological cost, therefore
explaining the overall low prevalence of fosfomycin
resistance in E. coli [14]. By contrast to chromosomal muta-
tions, production of a FosA-like enzyme has been estimated to
generate a lower biological cost and therefore may be prone to
be easily disseminated [23].
Finally, this study represents the first extended survey eval-
uating the performance of the rapid fosfomycin/E. coliNP test
for rapid screening of fosfomycin resistance in a large collec-
tion of clinical isolates. Thanks to its excellent performance,
this test whose results are given in less than 2 h and is low cost
might be widely implemented to accurately monitor the evo-
lution of fosfomycin resistance rates worldwide and is adapted
to rapid determination of fosfomycin susceptibility for an
adapted antibiotic stewardship of septicemia.
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